Insider · CIK 0001845080

Lee Philina

Reports to the SEC for 3 companies · CHATILLON

sec.gov

Transactions

Companies

Filings

CIK

0001845080

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-07-17	Blueprint Medicines CorpA Award	Chief Commercial Officer	AAward	+21.4K sh	—	—	63,349
2025-07-17	Blueprint Medicines CorpD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−50.2K sh	—	—	13,184
2025-07-17	Blueprint Medicines CorpU Disposition from Tender	Chief Commercial Officer	UDisposition from Tender	−13.2K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−8,650 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−6,928 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−20.7K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−25K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−22K sh	—	—	0
2025-03-05	Blueprint Medicines CorpS Sale	Chief Commercial Officer	SSale	−3,733 sh	$88.80	−$331K	41,996
2025-03-01	Blueprint Medicines CorpA Award	Chief Commercial Officer	AAward	+11K sh	—	—	45,729
2025-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+22K sh	—	—	22,000
2024-08-05	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+157 sh	$36.05	+$5,659.85	34,886
2024-08-05	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+1,042 sh	$51.06	+$53.2K	35,928
2024-08-05	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+5,011 sh	$81.44	+$408K	40,939
2024-08-05	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+4,331 sh	$43.15	+$187K	45,270
2024-08-05	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+8,450 sh	$54.13	+$457K	53,720
2024-08-05	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+10.6K sh	$61.31	+$648K	64,292
2024-08-05	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+12.4K sh	$86.60	+$1.07M	76,642
2024-08-05	Blueprint Medicines CorpS Sale	Chief Commercial Officer	SSale	−41.9K sh	$93.19	−$3.91M	34,729
2024-08-05	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−157 sh	—	—	0
2024-08-05	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−1,042 sh	—	—	0
2024-08-05	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−5,011 sh	—	—	0
2024-08-05	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−4,331 sh	—	—	20,669
2024-08-05	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−8,450 sh	—	—	0
2024-08-05	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−10.6K sh	—	—	6,928
2024-08-05	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−12.4K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−30K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2024-03-13	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+523 sh	$8.80	+$4,602.4	41,528
2024-03-13	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+1,224 sh	$15.01	+$18.4K	42,752
2024-03-13	Blueprint Medicines CorpS Sale	Chief Commercial Officer	SSale	−6,223 sh	$90.55	−$563K	36,529
2024-03-13	Blueprint Medicines CorpS Sale	Chief Commercial Officer	SSale	−1,800 sh	$89.88	−$162K	34,729
2024-03-07	Blueprint Medicines CorpS Sale	Chief Commercial Officer	SSale	−2,934 sh	$90.69	−$266K	41,005
2024-03-01	Blueprint Medicines CorpA Award	Chief Commercial Officer	AAward	+12.5K sh	—	—	43,939
2024-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+25K sh	—	—	25,000
2023-12-13	Blueprint Medicines CorpM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+261 sh	$1.87	+$488.07	31,439
2023-12-13	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−261 sh	—	—	0
2023-06-14	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)A Award	Director	AAward	+17K sh	—	—	17,000
2023-03-06	Blueprint Medicines CorpS Sale	Chief Commercial Officer	SSale	−1,622 sh	$45.72	−$74.2K	31,232
2023-03-06	Blueprint Medicines CorpS Sale	Chief Commercial Officer	SSale	−54 sh	$44.40	−$2,397.6	31,178
2023-03-01	Blueprint Medicines CorpA Award	Chief Commercial Officer	AAward	+12.5K sh	—	—	32,854
2023-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+25K sh	—	—	25,000
2022-06-14	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)A Award	Director	AAward	+17K sh	—	—	17,000
2021-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)A Award	Director	AAward	+17K sh	—	—	17,000
2021-02-11	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000

Recent filings

Accepted (ET)
Jul 214
Lee Philina0001104659-25-069378
SEC(opens sec.gov)
Mar 74
Lee Philina0001415889-25-007396
SEC(opens sec.gov)
Mar 44
Lee Philina0001415889-25-006609
SEC(opens sec.gov)
Aug 74
Lee Philina0001415889-24-020928
SEC(opens sec.gov)

Companies

Address

C/O DBV TECHNOLOGIES S.A. 107, AVENUE DE LA REPUBLIQUE

CHATILLON, 92320